Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their target price on Aethlon Medical from $23.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, March 4th.

Aethlon Medical Stock Up 3.2 %

AEMD opened at $1.46 on Friday. The company has a market cap of $3.83 million, a P/E ratio of -0.29 and a beta of 1.88. The firm’s 50-day moving average price is $1.66 and its 200-day moving average price is $1.77. Aethlon Medical has a 52-week low of $1.35 and a 52-week high of $7.20.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.14). On average, research analysts anticipate that Aethlon Medical will post -4.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Aethlon Medical

A number of institutional investors have recently bought and sold shares of AEMD. Two Sigma Investments LP boosted its holdings in Aethlon Medical by 219.3% in the first quarter. Two Sigma Investments LP now owns 127,341 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 87,458 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Aethlon Medical by 895.7% in the 4th quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 126,160 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Aethlon Medical by 61.4% in the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 38,264 shares during the last quarter. HRT Financial LP purchased a new stake in shares of Aethlon Medical in the fourth quarter worth about $28,000. Finally, Vanguard Group Inc. grew its holdings in Aethlon Medical by 112.9% during the third quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock worth $613,000 after acquiring an additional 558,596 shares during the period. 1.99% of the stock is owned by hedge funds and other institutional investors.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.